遠地點療法

2023年7月17日

5天改變今天上午06:16分享(聯盟新聞)——環球套票生物技術機會有限公司周一報道成功的首次公開發行(ipo)的整體投資組合的投資對象和一些收益,但表示其資產淨值下降。紐約投資公司,專注於生命科學領域,稱其資產淨值在6月30日每股1.68美元,比前一個月下降了2.4%。在倫敦的股票下跌0.4%,報1.32美元周一早晨。RTW表示,其第二季度私人投資活動增加的Abdera療法(aapl . o:行情)的投資組合,與領頭者Acelyrin . n:行情)和電氣石生物公司上市期間。四個投資組合公司上半年上市,都在“健康保險費之前RTW的私人持有的價值觀。”"Pharma went shopping in the first half," RTW added, saying that mergers and acquisitions in the sector totalled USD93 billion, "on track to be the highest since 2019." However, it said recovery in the biotechnology sector is currently "anaemic" as a focus on AI outshining other growth opportunities. RTW meanwhile said its portfolio company, Massachusetts-based Apogee Therapeutics Inc, raised USD300 million through its upsized IPO, offering 17.7 million shares at USD17.00 each. RTW also said Apogee's stock surged 25% to close at USD21.23 per share on Friday, its first day of trading on Nasdaq. Apogee represented 0.6% of RTW's NAV at June 30. "Apogee's IPO is the third in our portfolio so far this year (and fifth go-public event). As full life cycle investors, we are excited to continue to partner with the team in its efforts to develop new treatments for patients with inflammatory conditions," said Roderick Wong, chief investment officer at RTW's investment manager. "We also hope that such a strong market debut from a pre-clinical company may presage a better IPO environment ahead." By Emma Curzon, Alliance News reporter